A Review of the Virological Efficacy of the 4 World Health Organization–Recommended Tenofovir-Containing Regimens for Initial HIV Therapy

DSpace/Manakin Repository

A Review of the Virological Efficacy of the 4 World Health Organization–Recommended Tenofovir-Containing Regimens for Initial HIV Therapy

Citable link to this page

 

 
Title: A Review of the Virological Efficacy of the 4 World Health Organization–Recommended Tenofovir-Containing Regimens for Initial HIV Therapy
Author: Tang, Michele W.; Shafer, Robert W.; Kanki, Phyllis Jean

Note: Order does not necessarily reflect citation order of authors.

Citation: Tang, Michele W., Phyllis J. Kanki, and Robert W. Shafer. 2012. A review of the virological efficacy of the 4 world health organization–recommended tenofovir-containing regimens for initial HIV therapy. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 54(6): 862-875.
Full Text & Related Files:
Abstract: We systematically reviewed studies of the virological efficacy of the 4 new tenofovir (TDF)-containing regimens recommended for initial antiretroviral (ARV) therapy in the 2010 World Health Organization ARV Treatment Guidelines. Thirty-three studies assessed the efficacy of 1 or more TDF-containing regimens: TDF/lamivudine (3TC)/nevirapine (NVP) (n 5 3), TDF/ emtricitabine (FTC)/NVP (n 5 9), TDF/3TC/efavirenz (EFV) (n 5 6), and TDF/FTC/EFV (n 5 19). TDF/3TC/NVP was the least well-studied and appeared the least efficacious of the 4 regimens. In 2 comparative studies, TDF/3TC/NVP was associated with significantly more virological failure than AZT/3TC/NVP; a third study was terminated prematurely because of early virological failure. TDF/FTC/NVP was either equivalent or inferior to its comparator arms. TDF/3TC/EFV was equivalent to its comparator arms. TDF/FTC/EFV was equivalent or superior to its comparator arms. Possible explanations for these findings include the greater antiviral activity of EFV versus NVP and longer intracellular half-life of FTC-triphosphate versus 3TC-triphosphate. Further study of TDF/3TC/NVP is required before it is widely deployed for initial ARV therapy.
Published Version: doi:10.1093/cid/cir1034
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3284210/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:8715418
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters